Sangamo Therapeutics. has been granted a patent for nucleases designed to modify the CFTR gene, along with methods for creating cells and animal models. The patent includes a claim for a fusion molecule that combines a functional domain with a DNA-binding domain targeting specific sites. GlobalData’s report on Sangamo Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sangamo Therapeutics, Zinc-finger nucleases was a key innovation area identified from patents. Sangamo Therapeutics's grant share as of July 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Nucleases for cftr gene alteration and model generation
The granted patent US12043650B2 outlines a series of claims related to a fusion molecule that combines a functional domain with a DNA-binding domain, specifically designed to target and modify cystic fibrosis transmembrane conductance regulator (CFTR) genes. The claims include a polynucleotide encoding this fusion molecule, as well as various vectors—both viral and non-viral—that incorporate the polynucleotide. Notably, the patent specifies the use of an adeno-associated virus (AAV) vector and describes compositions and isolated cells that contain the fusion molecule. Additionally, the patent details methods for modifying CFTR genes in isolated cells, including the introduction of zinc finger nucleases to cleave and alter the CFTR gene, potentially correcting mutations such as the AF508 variant.
Further claims elaborate on the methods of integrating transgenes into the CFTR gene, which may involve inserting or deleting sequences to restore functional CFTR protein expression. The patent also covers genetically modified cells that have undergone these modifications, including lung cells and stem cells. Moreover, it describes a method for creating a cell or cell line with a mutant CFTR gene by mutating a wild-type gene using the specified nuclease. Lastly, the patent includes provisions for a kit containing the polynucleotide, as well as isolated cells that incorporate this polynucleotide, indicating a comprehensive approach to gene editing and potential therapeutic applications for cystic fibrosis.
To know more about GlobalData’s detailed insights on Sangamo Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
